in the complex of supportive periodontal therapy was established, which allows us to
recommend this complex
Vaiman, E.E.,
Shnayder, N.A.,
Zhuravlev, N.M.,
Petrova, M.M.,
Asadullin, A.R.,
Al-Zamil, M.,
Garganeeva, N.R.,
Shipulin, G.A.,
Cumming, G.,
Nasyrova, R.F. (2022) (low, moderate, high). We
recommend implementation in protocols of primary diagnosis of AP-induced LQTS
Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа1, the use of ketotifen and a kit/ fms kinase inhibitor is
recommended. Macrophages and T
Han, Dayong,
Teng, Lei,
Wang, Xiaoxiong,
Zhen, Yunbo,
Chen, Xiaofeng,
Yang, Mingchun,
Gao, Ming,
Yang, Guang,
Han, Mingyang,
Wang, Ligang,
Xu, Jiajun,
Li, Yue,
Shumadalova, Alina,
Zhao, Shiguang (2022) , and the dose
recommended for a phase II trial is 1.5 mg. Copyright © 2022 Han, Teng, Wang, Zhen, Chen, Yang